Giant Biogene (2367.HK) - The Key to Valuation Expansion and Short-Term Catalyst

943 Views11 Nov 2024 00:55

For recombinant collagen, Class III medical devices are the core performance driver for future growth, but Giant Biogene faces the challenge of delayed approval, which affects growth potential/outlook

What is covered in the Full Insight:

Introduction to Giant Biogene
Performance Overview of 24H1
Challenges with Class III Medical Device Approvals
Competitive Landscape and Market Expectations
Valuation and Future Outlook

Boomeranged on Thu, 17 Apr 2025 02:38

Giant Biogene announced a HK$2.294bn Placement with the price of HK$66.65/Share. Investment logic will change after Class III medical devices are approved. Based on forecast, growth will be strong, with net profit to reach RMB3.05bn (up 48% YoY) in 2025, RMB4.3bn (up 42% YoY) in 2026, RMB6.3bn (up 46% YoY) in 2027. P/E is 21.6x, 15x, 10x in 2025, 2026, 2027, respectively if based on HK$66.65/share

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to: